Pressure intensifies on Novartis as bolt-on deal strategy faces major test
Phase 3negativeNegative
AI Analysis
Summary
A key asset from Novartis' $12 billion acquisition of Avidity has failed in a Phase III trial, causing significant pressure on the company's bolt-on deal strategy and leading to a decline in share prices.
Clinical Trial Data
Phase
Phase III
Primary Endpoint
Not Met
Outcome Details
Key asset from Avidity deal failed in Phase III trial
Importance:8/10
Sentiment:
-0.80
Phase III failureM&ANovartisAvidityshare price decline
Read the original article
Published by Pharmaceutical Technology on September 14, 2026 10:39 AM